Oramed Pharmaceuticals Inc. — Director's Dealing 2012

Sep 6, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2012-08-28

Reporting Person: REGALS CAPITAL MANAGEMENT LP (10% Owner)
Reporting Person: Regals Fund LP (10% Owner)
Reporting Person: Slager David Mark (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8722265	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants (Right to Purchase)	$.37	2016-01-10	Common Stock (2956081)		Indirect
Warrants (Right to Purchase)	$.5	2017-08-28	Common Stock (1351352)		Indirect

Footnotes

F1: Regals Capital Management LP, a Delaware limited partnership ("Regals Management"), Regals Fund LP, a Delaware limited partnership (the "Fund"), and David M. Slager ("Mr. Slager"), are the reporting persons (the "Reporting Persons") for the referenced securities. Mr. Slager is Managing Member of the general partner of Regals Management. Regals Management is the investment manager of the Fund. The securities reported herein are held for the account of the Fund.

F2: As a result, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Fund for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended (the "Act"). Regals Management and Mr. Slager disclaim beneficial ownership within the meaning of Rule 16a-1(a)(4) under the Act in the securities owned by the Fund except to the extent, if any, of their pecuniary interest therein.

F3: The warrants are immediately exercisable.